Cytomegalovirus and polyomavirus BK posttransplant

Area of Science:

• Immunology
• Virology
• Transplantation Medicine

Background:

• Post-transplant viral infections, particularly cytomegalovirus (CMV) and BK virus (BKV), pose significant risks to patient and graft survival.
• Increased immunosuppression, while reducing graft rejection, enhances susceptibility to viral pathogens like CMV and BKV.
• CMV and BKV infections can lead to severe complications, affecting multiple organ systems and reducing long-term transplant outcomes.

Purpose of the Study:

• To review the diagnostic and therapeutic strategies for managing cytomegalovirus (CMV) and BK virus (BKV) infections in transplant patients.
• To highlight the challenges posed by CMV and BKV, including their impact on graft survival and the emergence of antiviral resistance.
• To discuss the current approaches to controlling these viral infections, emphasizing the role of immune modulation for BKV.

Main Methods:

• Literature review of diagnostic and therapeutic interventions for CMV and BKV post-transplantation.
• Analysis of the impact of immunosuppression on viral replication and disease progression.
• Examination of current treatment strategies, including antiviral therapies and immune-based approaches.

Main Results:

• Cytomegalovirus (CMV) remains a major viral pathogen post-transplant, causing widespread organ involvement and resistance to antivirals.
• BK virus (BKV) primarily affects the reno-urinary tract, leading to nephropathy and hemorrhagic cystitis, with treatment relying on immune reconstitution.
• Both CMV and BKV significantly reduce graft and patient survival, necessitating effective management strategies.

Conclusions:

• Effective management of CMV and BKV is crucial for improving outcomes in solid organ and hematopoietic stem cell transplant recipients.
• The development of novel diagnostic and therapeutic approaches is essential to combat viral infections and enhance long-term graft and patient survival.
• Balancing immunosuppression to control viral replication while preventing graft rejection remains a critical challenge in transplantation.